SVG103 — catalyst calendar
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2027-02 (month) in 4mo
ESTIMATED |
READOUT
Safety, Tolerability, and Pharmacokinetics of SVG103 (Paxalisib) in Focal Cortic
Phase 1/2 · Focal Cortical Dysplasia, Tuberous Sclerosis Complex (TSC) |
Sovargen | SVG103 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-10-02
Sponsor-projected date — can change
|